TrialClinical pharmacology and therapeutics2014

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

S Karovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.